Agios Pharmaceuticals, Inc. (AGIO) Director Lewis Clayton Jr. Cantley Sells 9,000 Shares of Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Lewis Clayton Jr. Cantley sold 9,000 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $56.36, for a total value of $507,240.00. Following the completion of the transaction, the director now owns 86,697 shares in the company, valued at approximately $4,886,242.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Get Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Lewis Clayton Jr. Cantley also recently made the following trade(s):

On Wednesday, July 19th, Lewis Clayton Jr. Cantley sold 3,500 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $56.14, for a total value of $196,490.00.
On Wednesday, June 14th, Lewis Clayton Jr. Cantley sold 2,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $50.87, for a total value of $101,740.00.
On Thursday, May 25th, Lewis Clayton Jr. Cantley sold 2,036 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $47.10, for a total value of $95,895.60.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded down 0.10% on Friday, hitting $57.17. The stock had a trading volume of 345,338 shares. The stock has a 50 day moving average price of $53.35 and a 200 day moving average price of $50.13. The company’s market cap is $2.76 billion. Agios Pharmaceuticals, Inc. has a 1-year low of $35.84 and a 1-year high of $67.74.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.56) EPS for the quarter, topping analysts’ consensus estimates of ($1.80) by $0.24. Agios Pharmaceuticals had a negative return on equity of 71.20% and a negative net margin of 491.54%. The firm had revenue of $10.51 million for the quarter, compared to analysts’ expectations of $9.65 million. During the same period in the previous year, the firm posted ($0.64) EPS. The business’s revenue for the quarter was down 66.4% compared to the same quarter last year. On average, equities research analysts expect that Agios Pharmaceuticals, Inc. will post ($6.44) EPS for the current fiscal year.

WARNING: This piece of content was originally published by [[site]] and is the property of of [[site]]. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at [[permalink]].

Several hedge funds have recently modified their holdings of the company. C WorldWide Group Holding A S bought a new stake in shares of Agios Pharmaceuticals during the first quarter worth approximately $105,000. Bank of Montreal Can boosted its stake in shares of Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 216 shares in the last quarter. Blue Sky Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals during the first quarter worth approximately $129,000. Russell Investments Group Ltd. boosted its stake in shares of Agios Pharmaceuticals by 163.9% in the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 1,583 shares in the last quarter. Finally, Advantage Investment Management LLC boosted its stake in shares of Agios Pharmaceuticals by 109.7% in the first quarter. Advantage Investment Management LLC now owns 3,250 shares of the biopharmaceutical company’s stock worth $190,000 after buying an additional 1,700 shares in the last quarter. 83.83% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have issued reports on the company. Janney Montgomery Scott lowered Agios Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, June 26th. BidaskClub upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 13th. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Credit Suisse Group AG reiterated an “outperform” rating and issued a $61.00 price target on shares of Agios Pharmaceuticals in a report on Tuesday, April 18th. Finally, Zacks Investment Research lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, April 18th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $62.88.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.